[go: up one dir, main page]

TN2011000307A1 - Galenic formulation of organic compounds - Google Patents

Galenic formulation of organic compounds

Info

Publication number
TN2011000307A1
TN2011000307A1 TN2011000307A TN2011000307A TN2011000307A1 TN 2011000307 A1 TN2011000307 A1 TN 2011000307A1 TN 2011000307 A TN2011000307 A TN 2011000307A TN 2011000307 A TN2011000307 A TN 2011000307A TN 2011000307 A1 TN2011000307 A1 TN 2011000307A1
Authority
TN
Tunisia
Prior art keywords
core
tablet
organic compounds
outer coating
dosage form
Prior art date
Application number
TN2011000307A
Other languages
English (en)
Inventor
Brethes Sabine Deset
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000307(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2011000307A1 publication Critical patent/TN2011000307A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000307A 2009-01-28 2011-06-16 Galenic formulation of organic compounds TN2011000307A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28
PCT/EP2010/050886 WO2010086312A1 (fr) 2009-01-28 2010-01-27 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
TN2011000307A1 true TN2011000307A1 (en) 2012-12-17

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000307A TN2011000307A1 (en) 2009-01-28 2011-06-16 Galenic formulation of organic compounds

Country Status (27)

Country Link
US (1) US20110287100A1 (fr)
EP (1) EP2391345B1 (fr)
JP (1) JP2012516299A (fr)
KR (1) KR20110117199A (fr)
CN (1) CN102300558A (fr)
AR (1) AR075179A1 (fr)
AU (1) AU2010209787B2 (fr)
BR (1) BRPI1007452A2 (fr)
CA (1) CA2749531A1 (fr)
CL (1) CL2011001817A1 (fr)
CO (1) CO6400184A2 (fr)
EC (1) ECSP11011289A (fr)
ES (1) ES2525648T3 (fr)
IL (1) IL213918A0 (fr)
MA (1) MA33060B1 (fr)
MX (1) MX2011007779A (fr)
MY (1) MY153852A (fr)
NZ (1) NZ593622A (fr)
PE (1) PE20110943A1 (fr)
PL (1) PL2391345T3 (fr)
PT (1) PT2391345E (fr)
RU (1) RU2535090C2 (fr)
SG (1) SG172226A1 (fr)
TN (1) TN2011000307A1 (fr)
TW (1) TWI468191B (fr)
WO (1) WO2010086312A1 (fr)
ZA (1) ZA201104489B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (fr) * 2011-11-23 2013-05-29 PLS-Design GmbH Composition pharmaceutique pour le traitement des réactions allergiques
JP6810152B2 (ja) 2016-02-03 2021-01-06 ノバルティス アーゲー サクビトリルおよびバルサルタンの組合せの新規使用
JP7461295B2 (ja) * 2018-08-10 2024-04-03 キッセイ薬品工業株式会社 スクロオキシ水酸化鉄含有顆粒及び医薬組成物
WO2020169991A1 (fr) * 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Préservation de particules d'api à revêtement fonctionnel produites par des procédés de mélange sans solvant dans une suspension aqueuse
CN113453662A (zh) 2019-02-22 2021-09-28 康特伦英国斯温顿捷迪斯有限公司 储存期间药物颗粒包衣材料的团聚最小化以稳定化药物产品的崩解时间
GB2585412B (en) 2019-02-22 2023-10-04 Catalent Uk Swindon Zydis Ltd Minimizing aeration of suspensions during in-line mixing
US11166919B2 (en) 2019-02-22 2021-11-09 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
WO2021011538A1 (fr) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation
IL300129A (en) 2020-07-31 2023-03-01 Catalent Uk Swindon Zydis Ltd Pharmaceutical preparations containing a coated API
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025105451A1 (fr) * 2023-11-17 2025-05-22 第一三共ヘルスケア株式会社 Préparation solide
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
WO2004100871A2 (fr) * 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
MY144477A (en) 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
BRPI0509971A (pt) * 2004-04-15 2007-10-02 Reddys Lab Inc Dr uma forma de dosagem farmacêutica, comprimido e método de preparação
ATE551052T1 (de) * 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
RU2010116526A (ru) * 2007-09-28 2011-11-10 Новартис АГ (CH) Фармацевтическая комбинация алискирена и валсартана

Also Published As

Publication number Publication date
EP2391345A1 (fr) 2011-12-07
KR20110117199A (ko) 2011-10-26
CL2011001817A1 (es) 2012-01-13
EP2391345B1 (fr) 2014-09-03
HK1161125A1 (en) 2012-08-24
CA2749531A1 (fr) 2010-08-05
SG172226A1 (en) 2011-07-28
CO6400184A2 (es) 2012-03-15
MX2011007779A (es) 2011-08-12
US20110287100A1 (en) 2011-11-24
ZA201104489B (en) 2012-02-29
MA33060B1 (fr) 2012-02-01
AU2010209787A1 (en) 2011-07-14
MY153852A (en) 2015-03-31
RU2011135417A (ru) 2013-03-10
IL213918A0 (en) 2011-07-31
JP2012516299A (ja) 2012-07-19
RU2535090C2 (ru) 2014-12-10
PT2391345E (pt) 2014-12-03
ECSP11011289A (es) 2011-09-30
ES2525648T3 (es) 2014-12-26
BRPI1007452A2 (pt) 2016-02-16
CN102300558A (zh) 2011-12-28
AR075179A1 (es) 2011-03-16
AU2010209787B2 (en) 2013-06-06
TW201038300A (en) 2010-11-01
WO2010086312A1 (fr) 2010-08-05
PL2391345T3 (pl) 2015-03-31
TWI468191B (zh) 2015-01-11
PE20110943A1 (es) 2012-01-22
NZ593622A (en) 2013-12-20

Similar Documents

Publication Publication Date Title
TN2011000307A1 (en) Galenic formulation of organic compounds
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
NZ589437A (en) Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
WO2013101897A3 (fr) Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés
WO2012007159A3 (fr) Nouvelles formes médicamenteuses à rétention gastrique
WO2009085990A3 (fr) Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
NZ605469A (en) Nalbuphine-based formulations and uses thereof
TN2010000135A1 (en) Galenical formulations of organic compounds
PH12012502085A1 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
ME02474B (fr) Schémas thérapeutiques
WO2011037976A3 (fr) Formulations pharmaceutiques de pramipexole
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
WO2010012459A3 (fr) Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques
GB2455875B (en) A process for the preparation of an orally administered unit dose tablet
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
GB0703674D0 (en) A Process For The Preparation of an Orally Administered Unit Dose Tablet
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
WO2013098268A3 (fr) Comprimés et agents enrobés à sec
GB0920721D0 (en) An orally administered anthelmintic unit dose tablet and process for the preparation thereof
WO2010013925A3 (fr) Composition pharmacologique destinée à la prévention et au traitement d’une maladie respiratoire, contenant un composé de pyrazolopyrimidinone ou des sels pharmaceutiquement acceptables de celui-ci